Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature

References

• KurdSKGelfandJMThe prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003–2004J Am Acad Dermatol20096021822419022533
   PubMed Web of Science ®Google Scholar
• PariserDMBagelJGelfandJNational Psoriasis Foundation Clinical Consensus on Disease SeverityArch Dermatol200714323924217310004
   PubMed Web of Science ®Google Scholar
• GladmanDAntoniCMeasePCleggDONashPPsoriatic arthritis: epidemiology, clinical features, course, and outcomeAnn Rheum Dis200564ii14ii1715708927
   PubMed Web of Science ®Google Scholar
• TzuJKerdelFFrom conventional to cutting edge: the new era of biologics in the treatment of psoriasisDermatol Ther20082113114118394087
   PubMed Web of Science ®Google Scholar
• GelfandJMShinDBNeimannALWangXMargolisDJTroxelABThe risk of lymphoma in patients with psoriasisJ Invest Dermatol20061262194220116741509
   PubMed Web of Science ®Google Scholar
• GelfandJMNeimannALShinDBRisk of myocardial infarction in patients with psoriasisJAMA20062961735174117032986
   PubMed Web of Science ®Google Scholar
• KremersHMMcEvoyMTDannFJHeart disease in psoriasisJ Am Acad Dermatol20075734735417433490
   PubMed Web of Science ®Google Scholar
• GelfandJMTroxelABLewisJDThe risk of mortality in patients with psoriasis: results from a population-based studyArch Dermatol20071431493149918086997
   PubMed Web of Science ®Google Scholar
• SchmittJMFordDERole of depression in quality of life for patients with psoriasisDermatology2007215172717587835
   PubMed Web of Science ®Google Scholar
• AlwawiEMehlisSGordonKTreating psoriasis with adalimumabTher Clin Risk Manag2008434545118728850
   PubMedGoogle Scholar
• BlauveltAT-Helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasisJ Investig Dermatol20081281064106618408745
   PubMed Web of Science ®Google Scholar
• PapoutsakiMChimentiMSCostanzoAAdalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologicsJ Am Acad Dermatol20075726927517574299
   PubMed Web of Science ®Google Scholar
• NestorovIClinical pharmacokinetics of TNF antagonists: how do they differ?Semin Arthritis Rheum200534121815852249
   PubMed Web of Science ®Google Scholar
• MenterAGottliebAGuidelines of care for the management of psoriasis and psoriatic arthritisJ Am Acad Dermatol20085882685018423260
   PubMed Web of Science ®Google Scholar
• GrannemanRGZhangYNoertersheuserPAVelagapudiRBAwniWMLockeCSPharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRA, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trialsArthritis Rheum200348S140S141
   Web of Science ®Google Scholar
• TraczewskiPRudnickaLAdalimumab in dermatologyBr J Clin Pharmacol20086661862518754844
   PubMed Web of Science ®Google Scholar
• KaineJEffect of adalimumab (HUMIRA®) on response to pneumococcal and influenza virus vaccines in patients with rheumatoid arthritis (RA) [poster] EULAR2006
   Google Scholar
• JohnsonDJonesKChambersCPregnancy outcomes in women exposed to adalimumabUniversity of California, San Diego, La Jolla, CA [abstract]2009 Annual Meeting of the Canadian Digestive Disease Week (CDDW) held jointly with the 5th Annual Meeting of the Canadian Association for the Study of the Liver (CASF)February 27–March 2, 2009 Abstract 34. Available at: Medical Intelligence Solutions 5198208.pdf.
   Google Scholar
• CarterJDLadhaniARiccaLRValerianoJVaseyFBA safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration DatabaseJ Rheumatol20093663564119132789
   PubMed Web of Science ®Google Scholar
• SaracenoRChimentiSHow to manage infections in the era of biologics?Dermatol Ther2008818018618564248
   PubMed Web of Science ®Google Scholar
• BaecklundEIliadouAAsklingJAssociation of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis Rheum20065469270116508929
   PubMed Web of Science ®Google Scholar
• ListingJStrangfeldAKekowJDoes tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?Arthritis Rheum20085863764018311805
   PubMed Web of Science ®Google Scholar
• Sarzi-PuttiniPAtzeniFShoenfeldYFerraccioliGTNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemmaAutoimmun Rev2005415316115823501
   PubMed Web of Science ®Google Scholar
• DommSCinatlJMrowietzUThe impact of treatment with tumor necrosis factor-α antagonists on the curse of chronic viral infections: a review of the literatureBr J Dermatol20081591217122818945310
   PubMed Web of Science ®Google Scholar
• FlendriesMVissersWCreemersMDe JongEVan de KerkhofPVan RielPDermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective studyArthritis Res Ther20057R666R67615899052
   PubMed Web of Science ®Google Scholar
• ErikssonCEngstrandSSundqvistKGRantapaa-Dahlqvist. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFαAnn Rheum Dis20056440340715297281
   PubMed Web of Science ®Google Scholar
• SchiffMHBurmesterGRKentJDPanganALKupperHSafety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketingAnn Rheum Dis20066588989416439435
   PubMed Web of Science ®Google Scholar
• LedingtonJDeightonCon behalf of the BSRUpdate on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)Rheumatology20054415716315637039
   PubMed Web of Science ®Google Scholar
• Van RijthovenAWBijlsmaJWCanninga-van DijkMDerksenRHvan RoonJAOnset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody levelRheumatology2006451317131916844698
   PubMed Web of Science ®Google Scholar
• SpillaneAPXiaYSniezekPJDrug-induced lupus erythematosus in a patient treated with adalimumabJ Am Acad Dermatol2007S114S11517434034
   PubMed Web of Science ®Google Scholar
• ShethNGreenblattDPatelSAclandKAdalimumab-induced cutaneous lupusClin Exp Dermatol20073259359417692063
   PubMed Web of Science ®Google Scholar
• MeasePJOryPSharpJTAdalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)Ann Rheum Dis20096870270918684743
   PubMed Web of Science ®Google Scholar
• HeibergMSKoldingsnesWMikkelsenKThe comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter studyArthritis Rheum20085923424018240258
   PubMed Web of Science ®Google Scholar
• GordonKBLangleyRGLeonardiCClinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyJ Am Acad Dermatol20065559860617010738
   PubMed Web of Science ®Google Scholar
• MenterATyringSKGordonKAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJ Am Acad Dermatol20085810611517936411
   PubMed Web of Science ®Google Scholar
• VanLModiSVYangDJHsuSSustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatmentArch Dermatol200814480480618559778
   PubMed Web of Science ®Google Scholar
• SchmittJZhangZWozelGMeurerMKirchWEfficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trialsBr J Dermatol200815951352618627372
   PubMed Web of Science ®Google Scholar
• GordonKBEfficacy and safety results in patients with psoriasis treated continuously with adalimumab for 100 weeks2008 Fall Clinical Dermatology ConferenceOct 16–19, 2008Las Vegas
   Google Scholar
• MeasePJSustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis: 2 years result from an open label extension studyPresented at Winter AAD Meeting2008San Antonio, TX
   Google Scholar
• BurmesterGRMeasePJDijkmansBAAdalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseasesAnn Rheum Dis2009681863186919147611
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDRitchlinCTAdalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialArthritis Rheum2005523279328916200601
   PubMed Web of Science ®Google Scholar
• GladmanDDMeasePJRitchlinCTAdalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trialArthritis Rheum20075647648817265483
   PubMed Web of Science ®Google Scholar
• SauratJHStinglGDubertretLEfficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs. placebo in patients with psoriasis (CHAMPION)Br J Dermatol200815855856618047523
   PubMed Web of Science ®Google Scholar
• GenoveseMCMeasePJThomsonGTSafety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapyJ Rheumatol2007341040105017444593
   PubMed Web of Science ®Google Scholar
• TubachFRavaudPSalmon-CeronDEmergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonistsClin Infect Dis200643e95e10017051484
   PubMed Web of Science ®Google Scholar
• ChungJHVan StavernGPFrohmanLPAdalimumab-associated optic neuritisJ Neurol Sci200624413313616527311
   PubMed Web of Science ®Google Scholar
• FulchieroGJJrSalvaggioHDrabickJJEruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapiesJ Am Acad Dermatol200756S65S6717434043
   PubMed Web of Science ®Google Scholar
• DengAHarveyVSinaBInterstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitorsArch Dermatol200614219820216490847
   PubMed Web of Science ®Google Scholar
• GoiizRDaudénEPeréz-GalaSGuhlGGarcia-DiezAFlare and change of psoriasis morphology during the course of treatment with tumor necrosis factor blockersClin Exp Dermatol20073217617917176269
   PubMed Web of Science ®Google Scholar
• CollamerANGuerreroKTHenningJSPsoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of actionArthritis Rheum200859996100118576309
   PubMed Web of Science ®Google Scholar
• WollinaUHanselGKochATumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patientsAm J Clin Dermatol2008911418092839
   PubMed Web of Science ®Google Scholar
• DalmauJRoeECorellaFAcute generalized skin eruption due to adalimumab: report of two casesJ Eur Acad Dermatol Venereol2007211105110617714134
   PubMed Web of Science ®Google Scholar
• ZangrilliAPapoutsakiMTalamontiMLong-term efficacy of adalimumab in generalized pustular psoriasisJ Dermatolog Treat20081918518718569276
   PubMed Web of Science ®Google Scholar
• CallenJPJacksonJHAdalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescentJ Dermatolog Treat20051635035216428160
   PubMed Web of Science ®Google Scholar